Rhinocerebral mucormycosis: a case series

Authors

  • Basavaraj N. Walikar Department of ENT, Al Ameen Medical College, Athani Road, Vijayapura, Karnataka
  • Anand N. Patil Department of General Medicine, Al Ameen Medical College, Athani Road, Vijayapura, Karnataka
  • Raveendra M. Madraki DM Nephrology, Yashodha Hospital, Solapur Road, Vijayapura, Karnataka
  • Wasifa S. Biradar Department of ENT, Al Ameen Medical College, Athani Road, Vijayapura, Karnataka
  • Yashaswini K. Department of ENT, Al Ameen Medical College, Athani Road, Vijayapura, Karnataka

DOI:

https://doi.org/10.18203/issn.2454-5929.ijohns20175631

Keywords:

Amphotericin, Liposomal amphotericin, Dialysis, Renal failure

Abstract

Background: The study is aimed to evaluate the role played by predisposing conditions like diabetes mellitus and precipitating factors like renal failure are discussed briefly here.

Methods: The prospective study of treatment of rhinocerebral mucormycosis on dialysis for renal failure without control subjects was evaluated. Subjects were patients with uncontrolled diabetes with renal failure presenting with rhinocerebral mucormycosis. Complete blood count, renal function tests, CT scan of paranasal sinuses and brain, nasal endoscopy and biopsy was done in all the 10 patients.  

Results: Seven patients were on long term dialysis except one patient who was on dialysis for the first time. Amphotericin was started for all 10 patients. Seven patients who were on long term dialysis did not recover from mucormycosis and succumbed to death (70% patients showed 30.71±17.18 days prognosis). Three patients (30% patients), who were not on dialysis and had a lesser degree of renal failure, responded to aggressive antifungal and surgical debridement treatment, and recovered from infection.

Conclusions: Mucormycosis in patients on dialysis is fatal. Improvement in renal function is a favourable prognostic factor for the successful treatment of mucormycosis. 

References

Shekar V, Sikander J, Rangdhol V, Naidu M. Facial nerve paralysis: A case report of rare complication in uncontrolled diabetic patient with mucormycosis. J Nat Sci Biol Med. 2015;6:226-8.

Shinde RV, Karande GS, Mohite ST, Patil SR. Rhino-orbital mucormycosis in diabetes mellitus. J Clin Diagn Res. 2013;7:1145-7.

Singh I, Gupta V, Gupta SK, Goyal S, Kumar M, Singh A. Our experience in endoscopic management of mucormycosis: a case series and review of literature. Int J Otorhinolaryngol Head Neck Surg. 2017;3:465-71.

Fatterpekar GS, Arbealez MA, Maheashwari S, Castillo M. Fungal diseases of the paranasal sinuses. Semin Ultrasound CT MR. 1999;20:391-401.

Herrera DA, Dublin AB, Ormsby EL, Aminpour S, Howell LP. Imaging findings of rhinocerebral mucormycosis. Skull Base. 2009;19:117-25.

Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev. 2014;27:490-526.

Rougraff BT, Lawrence J, Davis K. Length of Symptoms Before Referral: Prognostic variable for high-grade soft tissue sarcoma? Clin Orthop Relat Res. 2012;470:706-11.

Ingram CW, Sennesh J, Cooper JN, Perfect JR. Disseminated zygomycosis :report of four cases and review. Rev Infect Dis. 1989;11:741-54.

Morrisson VA, Mcglave PB. Mucormycosis in the BMT population. Bone marrow Transplant. 1993;11:383-8.

Maertens J, Demuynck H, Verbeken EK, Zachée P, Verhoef GE, Vandenberghe P, et al. Mucormycosis in allogenic bone marrow transplant recipients :report of five cases and review of the role of iron overload in the pathogenesis. Bone marrow Transplant. 1999;24:307-12.

Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30:851-6.

Herbrecht R, Letscher-Bru V, Bowden RA, Kusne S, Anaissie EJ, Graybill JR, et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Micorbial Infect Dis. 2001;20;460-6.

Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogenic bone marrow transplant recepients. Clin Infect Dis. 2001;32:1319-24.

Chakrabarti A, Das A, Mandal J, Shivaprakash MR, George VK, Tarai B, Rao P, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol 2006;44:335-42.

Roden MM, Zaoutis Te, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis:a review of 929 reported cases. Clin Infect Dis. 2005;41:634-53.

Effat KG, Karam M, EL-Kabani A. Potts puffy tumour caused by mucormycosis. J Laryngol Otol. 2005;119:643-5.

Gleissner B, Schilling A, Anagnostopolous I, Seihl I, Thiel E. Improved outcome of zygomycosis in patients with haematological diseases? Leuk Lymphoma. 2004;45:1351-60.

Parfery, NA. Improved diagonis and prognosis of mucormycosis. A clinicopathologic study of 33 cases. Medicine (Baltimore). 1986;65:113-23.

Schell WA. Histopathology of fungal rhinosinusitis. Otolaryngol Clin North Am. 2000;33:251-76.

Epstein VA, Kern RC. Invasive fungal sinusitis and complications of rhinosinusitis. Otolaryngol Clin North Am. 2008;41:497-524.

Gillespie MB, O’Malley BW. An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient. Otolaryngol Clin North Am. 2000;33:323-34.

Parikh SL, Venkatraman G, DelGaudio JM. Invasive fungal sinusitis: a 15-year review from a single institution. Am J Rhinol. 2004;18:75-81.

Spellberg B, Ibrahim AS. Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep. 2010;12:423-9.

Downloads

Published

2017-12-22

Issue

Vol. 4 No. 1 (2018): January-February 2018

Section

Original Research Articles